Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
What we know Eli Lilly, the pharmaceutical company behind GLP-1 injection Zepbound, is working to bring its weight loss drug to the market in pill form
The small intestine naturally produces GLP-1s after eating in order to trigger insulin release from the pancreas (allowing the body to use food for energy) and block glucagon secretion (the hormone responsible for raising blood sugar)
Based on a preliminary evaluation of weight loss trajectory, the company believes that treatment duration beyond 28 days may provide further reductions in body weight
Research convinced me retatrutide might help because it targets three receptors instead of two
Oxid Med Cell Longev 2019:114
PMID: 28642676
